These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22008654)

  • 1. Lipid levels in the second year of life among HIV-infected and HIV-exposed uninfected Latin American children.
    Hazra R; Cohen RA; Gonin R; Monteiro JP; Hofer CB; Negra MD; Ruz NP;
    AIDS; 2012 Jan; 26(2):235-40. PubMed ID: 22008654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.
    Lainka E; Oezbek S; Falck M; Ndagijimana J; Niehues T
    Pediatrics; 2002 Nov; 110(5):e56. PubMed ID: 12415062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.
    Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
    Antivir Ther; 2005; 10(5):585-91. PubMed ID: 16152752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid profiles of Thai adult HIV-infected patients receiving protease inhibitors.
    Hiransuthikul N; Hiransuthikul P; Kanasook Y
    Southeast Asian J Trop Med Public Health; 2007 Jan; 38(1):69-77. PubMed ID: 17539249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania.
    Liu E; Armstrong C; Spiegelman D; Chalamilla G; Njelekela M; Hawkins C; Hertzmark E; Li N; Aris E; Muhihi A; Semu H; Fawzi W
    Clin Infect Dis; 2013 Jun; 56(12):1820-8. PubMed ID: 23449270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipids and lactate in human immunodeficiency virus-1 infected pregnancies with or without protease inhibitor-based therapy.
    Livingston EG; Cohn SE; Yang Y; Watts HD; Bardeguez AD; Jones TB; Smith LM; Umbleja T; McComsey GA
    Obstet Gynecol; 2007 Aug; 110(2 Pt 1):391-7. PubMed ID: 17666616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased serum lipids are associated with higher CD4 lymphocyte count in HIV-infected women.
    Floris-Moore M; Howard AA; Lo Y; Arnsten JH; Santoro N; Schoenbaum EE
    HIV Med; 2006 Oct; 7(7):421-30. PubMed ID: 16925727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipodystrophy in HIV-infected pediatric patients receiving protease inhibitors.
    Temple ME; Koranyi KI; Nahata MC
    Ann Pharmacother; 2003 Sep; 37(9):1214-8. PubMed ID: 12921501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperlipidemia associated with protease inhibitor therapy.
    Echevarria KL; Hardin TC; Smith JA
    Ann Pharmacother; 1999; 33(7-8):859-63. PubMed ID: 10466916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
    Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
    HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between dyslipidemia and insulin resistance in HIV-infected persons treated with highly active antiretroviral therapy.
    Swanson B; Keithley JK; Zeller JM; Sha BE
    Nutrition; 2004; 20(11-12):1022-5. PubMed ID: 15561494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy.
    Calza L; Manfredi R; Farneti B; Chiodo F
    Int J Antimicrob Agents; 2003 Jul; 22(1):54-9. PubMed ID: 12842328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
    Chang ES; Tetreault DD; Liu YT; Beall GN
    J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
    [No Abstract]   [Full Text] [Related]  

  • 18. Cord blood lipids in infants born to HIV-1-infected women treated with combination antiretroviral therapy.
    Melvin AJ; Kang M; Hitti J; Livingston E; Cohn SE; Stocker V; Ross AC; Watts H; McComsey GA
    Antivir Ther; 2008; 13(3):349-55. PubMed ID: 18572747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurodevelopmental functioning in HIV-infected infants and young children before and after the introduction of protease inhibitor-based highly active antiretroviral therapy.
    Lindsey JC; Malee KM; Brouwers P; Hughes MD;
    Pediatrics; 2007 Mar; 119(3):e681-93. PubMed ID: 17296781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.
    Martínez E; Domingo P; Galindo MJ; Milinkovic A; Arroyo JA; Baldovi F; Larrousse M; León A; de Lazzari E; Gatell JM
    Clin Infect Dis; 2004 Apr; 38(7):1017-23. PubMed ID: 15034836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.